PER-038-15已完成未知
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER STUDY TO COMPARE THE SAFETY AND EFFICACY OF OMADACYCLINE IV/PO TO LINEZOLID IV/PO FOR TREATING ADULT SUBJECTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Written and signed informed consent must be obtained before any assessment is performed.
- •2. Male or female, age 18 years or older.
- •3. Has a qualifying skin and skin structure infection. All qualifying lesions must be ≥ 75 cm2 in total surface area of contiguous involved tissue, calculated as the product of the maximum length (head-to-toe) multiplied by the maximum width (measured perpendicular to length) as measured by the investigator using a wound ruler. Involved tissue is defined as tissue exhibiting clear evidence of one or more of the following: erythema, edema or induration.
- •The classification of qualifying infections is shown below.
- •a. Wound infection – an infection characterized by purulent drainage from a wound with surrounding erythema, edema, and/or induration extending at least 5 cm in the shortest distance from the peripheral margin of the wound.
- •b. Cellulitis – a diffuse skin infection characterized by spreading areas of erythema, edema, and/or induration.
- •c. Major abscess – an infection characterized by a collection of pus within the dermis or deeper with surrounding erythema, edema, and/or induration extending at least 5 cm in the shortest distance from the peripheral margin of the abscess.
- •4. Has evidence of a systemic inflammatory response within the 24 hours prior to randomization, as indicated by ONE of the following:
- •● Elevated white blood cell (WBC) count (≥ 10,000 cells/mm3)or leukopenia (≤ 4,000 cells/mm3)
- •● Elevated immature neutrophils (≥ 15% band forms) regardless of total peripheral WBC count
- •● Lymphatic involvement: lymphangitis or lymphadenopathy that is proximal to and in a location that suggests drainage from the qualifying infection
- •● Fever or hypothermia documented by the investigator (oral or rectal temperature > 38.0°C [100.4°F] or < 36.0°C [95.5°F])
- •5. Females must have a negative urine pregnancy test at Screening and agree to comply with using a highly effective form of birth control (eg, abstinence, oral contraceptive, intrauterine device [IUD], barrier contraception [condom], tubal ligation, hysterectomy, bilateral oophorectomy, or vasectomized partner) from Screening through PTE. Males must agree to use a highly effective method of birth control with female partner(s) and must not donate sperm from Screening through Post Therapy Evaluation (PTE).
排除标准
- •1. Has received 1 or more doses of a potentially effective systemic antibacterial treatment within the 72 hour period prior to first dose of test article (a subject will be considered to have received a potentially effective systemic antibacterial treatment if the pathogen identified as causing the infection is shown to be susceptible to the antibacterial treatment given or, in the circumstance where a pathogen is not identified, if the antibacterial agent is approved for treatment of skin infections or is known to have activity against any of the leading Gram-positive causes of ABSSSI [eg, Staphylococcus aureus, Streptococcus species [spp.], Enterococcus spp.).
- •2. Has, for any reason, used a topical antibacterial agent(s) with specific antibacterial activity (eg, mupirocin, retapamulin, fusidic acid) continuously within the 72 hour period prior to first dose of test article, if applied to the skin for ≥ 72 hours.
- •3. Infections where the outcome is strongly influenced by factors other than protocol-defined treatment and procedures, that require antibacterial treatment for greater than 14 days, are associated with chronic skin lesions that may obscure determination of response even after successful bacterial eradication has been achieved, or are suspected or known to be caused by a pathogen resistant to either test article, eg:
- •● chronic (persistently present > 3 months) lesions, ulcers or wounds (eg, cellulitis contiguous with a diabetic foot ulcer)
- •● association with chronic dermatitis or any other chronic inflammatory skin lesion (eg, psoriasis, eczema)
- •● peri-rectal abscess (eg, buttock or perineal lesion likely to communicate with the rectum) or perineal infection
- •● infected decubitus (pressure) ulcers
- •● necrotizing fasciitis (infections with rapidly progressive destruction of tissue at or below the fascia)
- •● life-threatening infections, ie, require emergency surgery for the treatment (eg, progressive gangrene)
- •● infections in an area requiring surgery that in and of itself would cure the infection or remove the infected site (eg, amputation for vascular insufficiency)
- •● infections associated with severe vascular insufficiency (eg, peripheral vascular disease) or acute occlusion expected to require immediate revascularization
- •● infections associated with acute compartment syndrome expected to require extensive surgery to provide decompression
- •● infections accompanied by confirmed or suspected contiguous bone or joint infection (eg, osteomyelitis, septic arthritis, bursitis)
- •● bacteremic infections associated with an intravascular foreign body
- •● infections accompanied by another confirmed or suspected infection requiring systemic antibiotic therapy (eg, endocarditis, other endovascular infection, meningitis, visceral abscess, intra-abdominal infection, pneumonia, urinary tract infection)
- •● human or animal bites (infections associated with insect bites are NOT excluded)
- •● myonecrosis
- •● complicated by an immune deficiency in the subject (eg, ecthyma gangrenosum in a neutropenic subject)
- •● infections associated with the presence of a foreign body (eg, wood, metal, plastic, etc.) if the foreign body cannot be removed within 24 hours of first dose of test article
- •4. Has known or is clinically suspected for one or more of the following prior
研究者
相似试验
招募中
不适用
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER STUDY OF ADJUVANT NIVOLUMAB VERSUS PLACEBO IN SUBJECTS WITH HIGH RISK INVASIVE UROTHELIAL CARCINOMA.Malignant neoplasm of renal pelvis-C65 Malignant neoplasm of renal pelvis-C66 Malignant neoplasm of ureter-C67 Malignant neoplasm of bladderMalignant neoplasm of ureterMalignant neoplasm of bladderC65C66C67PER-006-16BRISTOL MYERS SQUIBB COMPANY,
进行中（未招募）
1 期
A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancerRecurrent or primary advanced (Stage III or IV) endometrial cancerMedDRA version: 21.0Level: PTClassification code: 10014741Term: Endometrial cancer stage IV Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10014740Term: Endometrial cancer stage III Class: 100000004864CTIS2023-506551-23-00Tesaro Inc.785
已完成
不适用
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS ICLAPRIM VERSUS VANCOMYCIN IN THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS SUSPECTED OR CONFIRMED TO BE DUE TO GRAM-POSITIVE PATHOGENS. REVIVE-1-L00 Staphylococcal scalded skin syndromeL00Staphylococcal scalded skin syndromePER-013-16Motif BioSciences Inc.,9
已完成
不适用
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY OF NIVOLUMAB, NIVOLUMAB IN COMBINATION WITH IPILIMUMAB, OR PLACEBO AS MAINTENANCE THERAPY IN SUBJECTS WITH EXTENSIVE-STAGE DISEASE SMALL CELL LUNG CANCER (ED-SCLC) AFTER COMPLETION OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY-C349 Bronchus or lung, unspecifiedBronchus or lung, unspecifiedC349PER-060-15BRISTOL MYERS SQUIBB COMPANY,2
进行中（未招募）
不适用
A trial to test a new antibiotic given by vein to be used for ComplicatedUrinary Tract infections by comparing it to a well known antibiotic,levofloxacin.Complicated Urinary Tract Infection, Including PyelonephritisMedDRA version: 14.1Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-023452-87-DECubist Pharmaceuticals, Inc.776